Supernus at Citibank and RBC Global Healthcare Conferences in February

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will be hosting investor meetings during Citi’s 2014 Global Healthcare Conference.

Date: Tuesday, February 25Place: The Hilton New York Hotel

Investors interested in arranging a meeting during this conference should contact their Citi representative.

Supernus also announced that management will provide a business update on the Company at the 2014 RBC Capital Markets Global Healthcare Conference.

Date: Wednesday, February 26Presentation Time: 9:00am ETPlace: The New York Palace, New York, NY

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Supernus Pharmaceuticals, Inc.Jack A. Khattar, President and CEOGregory S. Patrick, Vice President and CFO301-838-2591orInvestor Contact:Cockrell Group877-889-1972investorrelations@thecockrellgroup.comcockrellgroup.com

Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Aug 2024 to Sep 2024